AstraZeneca PLC (LON:AZN)

London flag London · Delayed Price · Currency is GBP · Price in GBX
11,500
-1,132 (-8.96%)
Aug 3, 2026, 5:07 PM GMT
Market Cap195.93B +9.9%
Revenue (ttm)46.25B +8.6%
Net Income7.87B +25.9%
EPS5.03 +25.8%
Shares Out 1.55B
PE Ratio25.09
Forward PE15.66
Dividend2.39 (1.89%)
Ex-Dividend DateAug 6, 2026
Volume8,827,696
Open12,282
Previous Close12,632
Day's Range11,416 - 12,282
52-Week Range10,524 - 15,732
Beta0.22
AnalystsBuy
Price Target15,844.49 (+37.31%)
Earnings DateJul 27, 2026

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]

Sector Healthcare
Founded 1992
Employees 96,100
Stock Exchange London Stock Exchange
Ticker Symbol AZN
Full Company Profile

Financial Performance

In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.

Financial numbers in USD Financial Statements

Analyst Summary

According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 15,844p, which is an increase of 37.31% from the latest price.

Price Target
15,844p
(37.31% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Is AstraZeneca PLC (AZN) a Bargain After 6.9% Drop? GF Value Says Undervalued

Is AstraZeneca PLC (AZN) a Bargain After 6.9% Drop? GF Value Says Undervalued

3 hours ago - GuruFocus

Goldman Sachs's Hader on why AstraZeneca's stock fell on news of possible merger with Bristol Myers

Asad Haider, Goldman Sachs Healthcare Analyst, joins 'Closing Bell Overtime' to talk a possible merger between Bristol Myers and AstraZeneca.

4 hours ago - CNBC

Soriot plots pharma Brexit: Labour's failures have alienated a national champion, says ALEX BRUMMER

Pascal Soriot, pictured, has been on a glorious path as AstraZeneca boss, cataputing the medicines giant to number two in the FTSE 100.

4 hours ago - This is Money

AZN Looks 12.5% Undervalued on GF Value™ as Dividend Remains Secure

AZN Looks 12.5% Undervalued on GF Value™ as Dividend Remains Secure

5 hours ago - GuruFocus

European Stocks Rise as Oil Prices Fall Amid US-Iran Tensions, AstraZeneca Drops

European Stocks Rise as Oil Prices Fall Amid US-Iran Tensions, AstraZeneca Drops

7 hours ago - GuruFocus

TD Cowen sees no strategic logic in an AstraZeneca-Bristol Myers merger

TD Cowen analyst Steve Scala doesn’t see logic in combination of AstraZeneca (AZN) and Bristol Myers (BMY). If combined, AstraZeneca’s 2027-2032 sales growth would be diluted by two percentage points,...

7 hours ago - TheFly

FTSE 100 Slips as AstraZeneca Falls on Merger Reports

London shares edged lower as AstraZeneca losses outweighed gains from housebuilders and shipping stocks. The post FTSE 100 Slips as AstraZeneca Falls on Merger Reports appeared first on Investomania .

7 hours ago - Investomania

AstraZeneca Shares Slide on $400bn Bristol Myers Merger Talks

AstraZeneca falls as investors question the value, risks and strategic logic behind a potential Bristol Myers deal. The post AstraZeneca Shares Slide on $400bn Bristol Myers Merger Talks appeared firs...

7 hours ago - Investomania

AZN Looks 14.0% Undervalued on GF Value™ Amid Dividend Sustainability Concerns

AZN Looks 14.0% Undervalued on GF Value™ Amid Dividend Sustainability Concerns

7 hours ago - GuruFocus

AstraZeneca Stock Plunges 7.7% on Reported $400 Billion Merger Talks

AstraZeneca Stock Plunges 7.7% on Reported $400 Billion Merger Talks

8 hours ago - GuruFocus

AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling • AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm Sir Pascal Soriot, ...

8 hours ago - The Guardian

AstraZeneca–Bristol Myers Squibb merger 'is not highly likely to happen,' says UBS' Michael Yee

Michael Yee, UBS global head of biotech research, joins 'Squawk on the Street' to discuss the potential mega-merger between UK pharmaceutical company AstraZeneca and its U.S. competitor Bristol Myers ...

8 hours ago - CNBC

Stocks mixed as AstraZeneca merger talk dents FTSE 100

The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.

9 hours ago - Evening Standard

AstraZeneca (AZN) Faces Significant Drop, Hits Lowest Level Since 2025

AstraZeneca (AZN) Faces Significant Drop, Hits Lowest Level Since 2025

9 hours ago - GuruFocus

Bristol-Myers stock: why AstraZeneca merger is unlikely to happen

Bristol-Myers Squibb (BMY) stock is declining this morning, reversing its premarket gains as Wall Street digests bombshell reports of a potential transatlantic merger with AstraZeneca (AZN). According...

10 hours ago - Invezz

AZN Looks 5.6% Undervalued on GF Value™

AZN Looks 5.6% Undervalued on GF Value™

10 hours ago - GuruFocus

Potential Merger Between Bristol-Myers Squibb (BMY) and AstraZeneca Raises Concerns

Potential Merger Between Bristol-Myers Squibb (BMY) and AstraZeneca Raises Concerns

11 hours ago - GuruFocus

AZN Looks 5.6% Undervalued on GF Value™ Amid Strong Dividend Fundamentals

AZN Looks 5.6% Undervalued on GF Value™ Amid Strong Dividend Fundamentals

11 hours ago - GuruFocus

Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca

Bristol Myers Squibb stock is surging Monday following a report of a potential mega-merger with a competitor.

11 hours ago - Investopedia

AstraZeneca (AZN) and Bristol Myers Squibb (BMY) Explore Potential Merger

AstraZeneca (AZN) and Bristol Myers Squibb (BMY) Explore Potential Merger

11 hours ago - GuruFocus

AstraZeneca (AZN) Stock Drops Amid Merger Talks with Bristol-Myers Squibb (BMY)

AstraZeneca (AZN) Stock Drops Amid Merger Talks with Bristol-Myers Squibb (BMY)

11 hours ago - GuruFocus

AstraZeneca Stock Nosedives On Mega-Merger Rumor

AstraZeneca stock took a nosedive Monday amid reports it's mulling a mega-merger with Bristol Myers Squibb.

12 hours ago - Investor's Business Daily

Video: Bristol Myers jumps, AstraZeneca sinks on report of tie-up talks

The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how the markets will open, which stocks will be moving and why. Published…

12 hours ago - TheFly

5 Things to Know Before the Stock Market Opens on Monday

Stock futures are pointing to a higher open to kick off August trading as investors look ahead to a packed week of earnings reports; oil prices are tumbling after the U.S. paused strikes on Iran over ...

13 hours ago - Investopedia